SEARCH

SEARCH BY CITATION

References

  • 1
    Fogle JE, Bissett SA. Mucosal immunity and chronic idiopathic enteropathies in dogs. Compend Contin Educ Vet 2007;29:290302.
  • 2
    Craven M, Simpson JW, Ridyard AE, et al. Canine inflammatory bowel disease: Retrospective analysis of diagnosis and outcome in 80 cases (1995–2002). J Small Anim Pract 2004;45:336342.
  • 3
    Araki Y, Tsujikawa T, Andoh A, et al. Therapeutic effects of an oral adsorbent on acute dextran sulphate sodium-induced colitis and its recovery phase in rats, especially effects of elimination of bile acids in gut lumen. Dig Liver Dis 2000;32:691698.
  • 4
    Anderson K, Fischer L. Prevention of GI absorption of bacterial toxins: An in vitro evaluation of the potential for prophylactic use of a novel oral adsorbent. Gastroenterology 2008;134:A675.
  • 5
    Anderson K, Tomiyana S, Nitta T. AST-120: A novel, engineered carbon microsphere product for use in chronic inflammatory bowel disease and liver dysfunction. Gastroenterology 2008;134:A675.
  • 6
    Ueda H, Shibahara N, Takagi S, et al. AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases. Ther Apher Dial 2007;11:189195.
  • 7
    Fukuda Y, Takazoe M, Sugita A, et al. Oral spherical adsorptive carbon for the treatment of intractable anal fistulas in Crohn's disease: A multicenter, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 2008;103:17211729.
  • 8
    Jergens AE, Schreiner CA, Frank DE, et al. A scoring index for disease activity in canine inflammatory bowel disease. J Vet Intern Med 2003;17:291297.
  • 9
    Willmer J, Anderson K, Proksch S, et al. Absence of pharmacokinetic drug-drug interactions in healthy volunteers between AST-120, a novel oral adsorbent and concomitant medications: CiproXR (CFXR) and azathioprine (AZA). Gut 2008;57(Suppl 2):A374.
  • 10
    Tack JF, Miner PB Jr, Fischer L, et al. Randomised clinical trial: The safety and efficacy of AST-120 in non-constipating irritable bowel syndrome – A double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011;34:868877.
  • 11
    Packey CD, Sartor RB. Interplay of commensal and pathogenic bacteria, genetic mutations, and immunoregulatory defects in the pathogenesis of inflammatory bowel diseases. J Intern Med 2008;263:597606.